GBT: Possible M&A Target By Year End? Mark Jukic Global Blood Therapeutics is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT’s lead product is GBT440, which is a treatment for sickle cell disease (SCD) and idiopathic pulmonary fibrosis (IPF). SCD is caused

Read More

AUPH: Are Investors Honestly Surprised With Results? By: Mark Jukic (Boul)   The time has finally come for Aurinia, and they shocked investors with an extremely positive readout for their Phase IIb study of Voclosporin (Lupus Nephritis). After positive PIIa and (now) PIIb data released (24 week and 48 week trials), we now go into

Read More